Crohn’s Disease Market - Trends and Forecast Till 2035

CROHN’S DISEASE MARKET: OVERVIEW

The global Crohn’s disease market is estimated to grow from USD 10.3 billion in the current year to USD 18.1 billion by 2035, registering a CAGR of 6.5% across the forecast period.

Crohn’s Disease Market: Growth and Trends

Crohn’s disease is a chronic inflammatory disorder of the gastrointestinal tract. It can affect any segment of the digestive system, though the small intestine and colon are most commonly involved. The disease follows a relapsing and remitting course, and its clinical presentation ranges from mild discomfort to severe, unbearable illness marked by strictures, fistulas, and malnutrition. This variability continues to complicate diagnosis and long-term disease management.

The treatment landscape is shifting toward targeted and individualized therapy. Biologic agents are now a cornerstone of treatment for moderate to severe disease, supported by strong physician confidence, broad reimbursement, and a growing range of approved therapies. Recent approvals of IL-23 inhibitors, including Omvoh and TREMFYA, alongside AbbVie’s Rinvoq, the first once-daily oral therapy for the indication, are broadening options for patients who no longer respond to older anti-TNF drugs.

The growing wave of biosimilar launches, including Wezlana, Amjevita, and Avsola, is reshaping the competitive and pricing landscape and improving patient access to biologic therapy. At the same time, developers are exploring cell therapy and novel integrin- and IL-23-targeted pathways for patients with treatment-refractory disease, signaling continued innovation ahead.

For pharmaceutical companies, the growing mix of infused, subcutaneous, and emerging oral therapies is reshaping demand across hospital, retail, and online pharmacy channels, creating new opportunities across the specialty pharmaceutical supply chain.

Growth Drivers: Factors Fueling Market Expansion

The Crohn’s disease market is primarily driven by the rising global prevalence of the condition. An estimated 1 million patients were living with Crohn’s disease in the US alone in 2023, and the CDC estimates that 2.4 to 3.1 million people in the country are living with inflammatory bowel disease overall. As diagnosis rates improve, demand for effective, long-term therapeutic solutions continues to build across care settings.

Continued advancements in targeted biologic therapies are reinforcing this trajectory. These agents provide better disease control and fewer limitations than older treatment options, encouraging innovation and strengthening physician adoption in moderate to severe patients. The rising use of JAK inhibitors and immunomodulators is further expanding the toolkit available to patients who do not respond adequately to conventional therapy, supporting sustained value growth across the market.

Market Challenges: Critical Barriers Hindering Progress

Despite favorable growth prospects, the market faces several challenges that may impede the market growth during the forecast period. Some of the significant challenges include high treatment costs and disease complexity. Notably, biologic therapies such as infliximab and ustekinumab carry annual treatment costs ranging from USD 45,000 to USD 90,000, limiting affordability for many patients and healthcare systems. Further, highly variable disease presentation also delays timely diagnosis, with one study finding that roughly half of Crohn’s disease patients waited more than two years to receive a diagnosis.

Adverse effects and safety concerns associated with immunosuppressive and biologic therapies, including elevated infection risk, add further hesitancy among physicians and patients. Addressing these cost, diagnostic, and safety challenges will be critical for stakeholders seeking to capture the full commercial opportunity within this space.

Recent Developments Signaling Investor Momentum

• Johnson & Johnson announced USFDA approval of Stelara for the treatment of patients aged two years and older with moderately to severely active Crohn’s disease.
• Teva Pharmaceuticals secured USD 400 million from Blackstone Life Sciences to advance clinical development of duvakitug for inflammatory bowel diseases, including Crohn’s disease.
• Agomab initiated an initial public offering to finance a Phase 2b trial of Ontunisertib, a candidate therapy for Crohn’s disease.
• Bio-Thera Solutions, in partnership with Hikma Pharmaceuticals, announced USFDA approval of STARJEMZA, a biosimilar of Stelara, for chronic inflammatory and autoimmune conditions including Crohn’s disease.

Collectively, these transactions underscore sustained investor and strategic-acquirer confidence in the Crohn’s disease pipeline, with biosimilar competition and novel-mechanism development as themes directly relevant to distributors and investors evaluating exposure to this market.

Currently Approved Drugs for Crohn’s Disease

A number of biologics and small molecules are approved for the treatment of Crohn’s disease. The most recent approval is Eli Lilly’s Omvoh, an IL-23 inhibitor for moderate to severe disease, cleared by the FDA in January 2025. In May 2023, AbbVie’s Rinvoq became the first once-daily pill approved for moderate to severe Crohn’s disease.

Crohn’s Disease Market Segments

The market sizing and opportunity analysis has been segmented across the following parameters:

By Drug Class

• Biologics
• Amino Salicylates
• Antibiotics
• Corticosteroids
• Immunomodulators
• Others

By Route of Administration

• Subcutaneous
• Intravenous
• Oral

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• Latin America

Crohn’s Disease Market: Key Segments

Biologics Lead the Drug Class Segment

Based on this market assessment, the biologics segment captures the majority of overall Crohn’s disease market revenue share. This dominance is largely because biologics have become the standard of care for moderate to severe disease, where conventional corticosteroids and immunomodulators are often insufficient for long-term control. AbbVie’s expanding portfolio, spanning HUMIRA, and Skyrizi illustrates how continued innovation in targeted mechanisms is reinforcing this segment’s dominance. Biologics are also expected to register the highest CAGR through the forecast period, driven by continued IL-23 inhibitor innovation.

Subcutaneous Route Dominates Administration

According to the Roots Analysis market report, the subcutaneous route captures highest share of the overall market by 2035. This largest share is supported by widely used maintenance products such as HUMIRA that allow standardized, fixed-dose, self-administered treatment at home. On the other hand, the oral segment, while smaller today, is projected to grow at a comparatively higher CAGR during the forecast period. This lucrative growth is largely because developers such as AbbVie advance next-generation oral small molecules that reduce dependence on facility-based administration.

Hospital Pharmacies Lead the Distribution Channel Segment

Hospital pharmacies currently hold the largest share of the Crohn’s disease distribution channel segment. This high share reflects the professional administration and monitoring required for infused biologics such as Takeda’s ENTYVIO. Meanwhile, the online pharmacy segment is expected to grow at a comparatively higher CAGR during the forecast period. This unprecedented growth is largely because home delivery and telehealth-enabled platforms reduce the burden of repeated in-person visits for patients managing unpredictable flare-ups.

North America Dominates the Geographical Segment

Based on the regional analysis, North America is projected to capture the highest share of Crohn’s disease market revenue by 2035. This dominance is supported by extensive specialist care networks and favorable reimbursement policies. The region’s scale is reinforced by developers such as AbbVie, headquartered in Illinois, alongside the substantial US disease burden tracked by the CDC. Asia-Pacific, meanwhile, is likely to register the fastest regional CAGR through the forecast period, aided by expanding healthcare infrastructure and rising biologic therapy availability.

Example Players in the Crohn’s Disease Market

• AbbVie
• Athos Therapeutics
• Eli Lilly and Company
• Janssen Biotech
• Pfizer
• Roche
• Sanofi
• Takeda

Expert Interview and Industry Insights

The opinions and insights presented in this study were shaped by discussions with multiple stakeholders across the value chain. Validating the market’s growth trajectory, Professor Jean-Frederic Colombel noted that a study conducted with the Crohn’s & Colitis Foundation found that roughly half of Crohn’s disease patients waited more than two years to receive a diagnosis, underscoring the scale of the unmet clinical need. The research report features detailed transcripts of interviews held with the following industry participants:

• Founder, Public Hospital, US
• Gastroenterology and Assistant Professor of Medicine, Public University, US
• Gastroenterologist, Mid-Sized Company, Germany
• Clinical Pharmacy Coordinator, Non-Profit Organization, US
• Gastroenterologist and Head of the Clinical Pharmacology, Public University, Portugal
• Gastroenterologist, Public Hospital, Spain
• Gastroenterologist, Public Hospital, Germany
• Gastroenterologist, Public Hospital, US
• Gastroenterologist, Public University, US
• Assistant Professor, Public University, US

CROHN’S DISEASE MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: An in-depth analysis of the global market focusing on key segments, including drug class, route of administration, distribution channel, and geographical regions.
• Market Landscape of Drugs and Therapy Programs: A detailed assessment of Crohn’s disease drug candidates by stage of development, type of molecule, type of biologic, drug frequency, route of administration, target pathway, target patient population, and developer size and headquarters.
• Clinical Commercial Attractiveness: An evaluation of Phase III drugs targeting Crohn’s disease, scored across key commercial and clinical parameters.
• Company Profiles: In-depth profiles of prominent players engaged in Crohn’s disease drug development, covering drug portfolios and key recent initiatives.
• Clinical Trial Analysis: A comprehensive analysis of registered clinical trials by registration year, status, phase, study design, target patient population, sponsor activity, and geography.
• Drug Failure Analysis: An assessment of discontinued Crohn’s disease drug candidates by trial phase, reason for discontinuation, and sponsor type.
• Market Impact Analysis: A structured review of the key drivers, restraints, opportunities, and challenges shaping the Crohn’s disease market.
• Revenue Shift and Penetration-Growth Analysis: An assessment of movement across geographical regions using a Penetration-Growth (P-G) Matrix to identify emerging opportunity areas.

KEY QUESTIONS ANSWERED IN THIS REPORT

• Which are the leading companies in the Crohn’s disease market?
• Which region dominates the market, and which is growing the fastest?
• What are the key trends observed in this market?
• What factors are likely to influence the evolution of this market?
• What are the primary challenges faced by drug developers and distributors in this space?
• What is the current and future market size?
• What is the CAGR of this market through 2035?
• How is current and future market opportunity distributed across key segments?
• What opportunities exist for distributors and channel partners entering this space?

REASONS TO BUY THIS REPORT

This report is designed to give distributors, channel partners, and investors a decisive analytical edge in a fast-evolving market. Its core differentiators include:

• Top-Down and Bottom-Up Triangulated Forecasting: Market estimates are built using a hybrid methodology that cross-validates top-down macro assessments against bottom-up, drug-level demand data, minimizing forecast bias.
• Distribution and Channel-Partner Lens: Unlike conventional drug pipeline reports, this study explicitly maps the hospital, retail, and online pharmacy opportunities available to distribution partners across the Crohn’s disease value chain.
• Primary Research-Backed Insights: Findings are validated through direct interviews with gastroenterologists, hospital leaders, and clinical pharmacy coordinators, ensuring insights reflect real clinical practice rather than desk research alone.
• Actionable Segmentation: Four-parameter segmentation (drug class, route of administration, distribution channel, geography) enables precise opportunity sizing for any go-to-market or investment thesis.
• Clinical Trial and Drug Failure Intelligence: Dedicated chapters on clinical trial activity and drug discontinuation trends provide an early read on which pipeline candidates are most likely to reach commercialization.

ADDITIONAL BENEFITS

• Complementary PPT Insights Pack
• Complementary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated Report if the Report is 6-12 Months Old or Older